|Day's range||33.28 - 33.28|
|52-week range||31.99 - 37.33|
|PE ratio (TTM)||N/A|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
CytoSorbents (CTSO) reported financial results for the fourth quarter ending December 31st and provided a business update. Total revenue and product sales continue to show considerable strength, rising for the seventh straight quarter and catalyzed by CytoSorb cartridge (“razor blade”) reorders as well as new customer wins and expansion of the distribution footprint. Both product sales and total revenue set new records in Q4. Q4 product sales were up 74% yoy and 22% sequentially to $2.6M. Meanwhile, total revenue (which along with product sales includes grant revenue) grew 75% yoy and 28% sequentially to $3.1M. As we have stressed in the past, we are encouraged by the high quality product revenue growth – that is, mostly reorders, no channel stuffing or lumpy distributor stocking – which we believe offers a certain level of validation of burgeoning demand and by extension, clinical utility of CytoSorb.
CytoSorbents (CTSO) has had a busy last couple of months leading up to the annual JP Morgan, Biotech Showcase and Medtech Showcase conferences which were held earlier this week in San Francisco and where management took some time to talk to us. Just prior to the company’s presentation at the Biotech Showcase they announced an expanded agreement with Fresenius and preannounced expected Q4 and FY2016 product sales. Per the January 10th preannouncement, CTSO expects Q4 product sales of ~$2.6M, implying sequential and yoy growth of approximately 21% and 74%, respectively, and marking the sixth straight quarter of record product sales. Product sales of $2.6M is also almost 16% higher than what we had forecast ($2.2M).
Abbott can now proceed with its $25 billion buy of St. Jude Medical.